Commission Implementing Regulation (EU) No 456/2012Dangos y teitl llawn

Commission Implementing Regulation (EU) No 456/2012

of 30 May 2012

amending Regulation (EC) No 1266/2007 on implementing rules for Council Directive 2000/75/EC as regards the control, monitoring, surveillance and restrictions on movements of certain animals of susceptible species in relation to bluetongue

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Council Directive 2000/75/EC of 20 November 2000 laying down specific provisions for the control and eradication of bluetongue(1), and in particular Article 9(1)(c), Articles 11 and 12 and the third paragraph of Article 19 thereof,

Whereas:

(1) Commission Regulation (EC) No 1266/2007(2) lays down rules for the control, monitoring, surveillance and restrictions on movements of animals, in relation to bluetongue, in and from the restricted zones. It also establishes the conditions for exemptions from the exit ban applicable to movements of susceptible animals, their semen, ova and embryos provided for in Directive 2000/75/EC, including rules on the use of vaccines against bluetongue.

(2) Under the current rules laid down in Directive 2000/75/EC, the use of vaccines against bluetongue is not permitted outside protection zones. Directive 2012/5/EU of the European Parliament and of the Council of 14 March 2012 amending Council Directive 2000/75/EC as regards vaccination against bluetongue(3) makes the rules on vaccination laid down in Directive 2000/75/EC more flexible in order to allow vaccination with inactivated vaccines against bluetongue also outside the areas subject to animal movement restrictions. As a consequence, Regulation (EC) No 1266/2007 should be amended. Furthermore, amendments are necessary to simplify the process of monitoring and surveillance and to adapt the procedures established by Regulation (EC) No 1266/2007 to recent scientific opinions.

(3) For the purpose of gathering and analysing epidemiological information on bluetongue, Regulation (EC) No 1266/2007 provides that Member States are to transmit to the BlueTongue NETwork application (BT-Net system) information on bluetongue gathered in the course of the implementation of the bluetongue monitoring and surveillance programmes.

(4) However, experience shows that there is sufficient information available in the framework of other existing Union disease notification and reporting obligations. The obligation to exchange information through the BT-Net system is therefore no longer necessary.

(5) Regulation (EC) No 1266/2007, as amended by Commission Regulation (EC) No 123/2009(4) introduced the possibility for Member States to demarcate, under certain conditions, ‘lower risk areas’ to facilitate preventive vaccination in parts of their territory without virus circulation. As a consequence of the entry into force of Directive 2012/5/EU, whereby vaccination against bluetongue may be performed also outside restricted zones the provisions for the demarcation of ‘lower risk areas’ are no longer necessary.

(6) In accordance with Article 6(2) of Regulation (EC) No 1266/2007, a Member State may decide to remove an epidemiological geographical relevant area from a restricted zone, and thereby claim freedom from disease in that area after two years of absence of virus circulation as proven by monitoring.

(7) However, those parts of a restricted zone where for at least one year, including a full vector activity season, monitoring and surveillance show that no virus circulation of a specific bluetongue serotype or serotypes has taken place, are at risk of reintroduction of the disease by introduction of infectious animals from other parts of the same restricted zone where the bluetongue virus is still circulating. For these situations, in order to provide for a safe transition towards freedom from disease under favourable epidemiological conditions, Member States should be allowed to demarcate a ‘provisionally free area’ subject to the condition that monitoring and surveillance to ascertain the absence of virus circulation is carried out.

(8) According to the Scientific Opinion of the Panel on Animal Health and Welfare of the EFSA on the ‘Risk of Bluetongue Transmission in Animal Transit’, adopted on 11 September 2008(5), there is a theoretical possibility that infectious midges co-travel with the animals. That risk might be controlled by cleaning the vehicle and treating it with insecticides or repellents before loading the animals or when moving animals through areas known to be at low risk or at a period of time when the risk is known to be low. In order to limit undesired effects to the environment of those substances and to avoid possible problems as regards waiting periods and possible residues in the animals, the treatment of animals with authorised insecticides or repellents should no longer be required as this treatment provides for limited additional safety.

(9) Regulation (EC) No 1266/2007, as amended by Implementing Regulation (EU) No 648/2011(6), allows, for a transitional period, Member States of destination, in which the introduction of non-immune animals under certain circumstances could pose a risk for animal health, to require that the movement of such animals is subject to certain additional conditions. As rules on criteria for vector protected establishments are laid down in this Regulation, that transitional provision is no longer necessary.

(10) Due to the different levels of virus circulation, environmental conditions and different vaccination strategies in the Member States, the epidemiological situations as regards bluetongue may differ considerably in different areas of the Union. Experience has shown that different surveillance strategies may be successfully implemented to achieve the desired objectives. Therefore, the minimum harmonised requirements for monitoring and surveillance as laid down in Annex I to Regulation (EC) No 1266/2007 should be simplified to allow for more flexibility for the Member States to design their national monitoring and surveillance programmes, taking into account the Scientific Opinion of the EFSA Panel on Animal Health and Welfare on bluetongue monitoring and surveillance(7).

(11) Based on the abovementioned Scientific Opinion, the minimum sample size to detect a prevalence of 5 % with 95 % confidence in the susceptible species population should be sufficient for surveillance for the purpose of demonstrating the absence of virus circulation in an epidemiological relevant geographical area during a period of two years.

(12) Keeping bluetongue susceptible animals in a vector proof establishment for a specified period of time is an important requirement for certain conditions for exemptions from the exit ban as set out in Annex III to Regulation (EC) No 1266/2007. Experience shows that it is difficult for Member States to establish proper criteria for the implementation of a vector proof establishment for regular movements for trade in animals of susceptible species such as cattle, sheep and goats.

(13) In order to improve the effectiveness of vector proof establishments and to assist the Member States in their implementation of that control measure, a number of criteria should be established. Those criteria should be based on experiences of the Member States and the Terrestrial Animal Health Code of the World Organisation for Animal Health (OIE). To align the terminology with the OIE, the term ‘vector proof establishment’, currently used in Regulation (EC) No 1266/2007, should be replaced by ‘vector protected establishment’.

(14) In response to new scientific information which indicates the possibility of transplacental transmission of the bluetongue virus, in particular for bluetongue virus serotype 8, precautionary measures to prevent the possible spread of bluetongue by pregnant animals or certain newborn animals were introduced in Regulation (EC) No 1266/2007, as amended by Regulation (EC) No 384/2008(8).

(15) According to the Scientific Opinion of the Panel on Animal Health and Welfare of the EFSA on bluetongue serotype 8(9), there is scientific evidence for transplacental transmission of bluetongue virus serotype 8 which was introduced in the Union in 2006. However, transplacental transmission of other serotypes of the bluetongue virus in affected areas where no modified live vaccines have been used has not been shown. In the light of the conclusions of that opinion, the precautionary measure as regards the movement of pregnant animals should only apply for zones which are restricted for bluetongue virus serotype 8.

(16) Regulation (EC) No 1266/2007 should therefore be amended accordingly.

(17) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health,

HAS ADOPTED THIS REGULATION:

(1)

OJ L 327, 22.12.2000, p. 74.

(2)

OJ L 283, 27.10.2007, p. 37.

(3)

OJ L 81, 21.3.2012, p. 1.

(4)

OJ L 40, 11.2.2009, p. 3.

(5)

EFSA Journal 2008; 795, 18-65.

(6)

OJ L 176, 5.7.2011, p. 18.

(7)

EFSA Journal 2011; 9(6): 2192.

(8)

OJ L 116, 30.4.2008, p. 3.

(9)

EFSA Journal 2011; 9(5): 2189.